In addition, on the base of the cleavage pattern of PARP protein, we divided the 12 patients treated with Bafetinib and Ibrutinib into “dependent” and “independent” groups showing no differences between the two groups on CLL B cell viability and Lyn as well as ERK de-phosphorylation (data not shown). The gene discussed is LYN; the disease is B-cell chronic lymphocytic leukemia.